Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133409) titled 'A Single-Center, Prospective, Single-Arm Clinical Study of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for 3 Cycles in Resectable Stage II-IIIA NSCLC' on Sept. 26.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University
Condition:
Non-small-cell lung cancer
Intervention:
Experimetal group:Serplulimab combined with chemotherapy (paclitaxel/nab-paclitaxel and platinum).
Serplulimab: fixed dose 300 mg, intravenous infusion over 30-90 min
chemotherapy administered after an interval of at least 30 min
Recruitment Sta...